|
The Serological Sciences Network (SeroNet)
|
Committee, Work group, Advisory group, or Task Force
|
FDA, CDC, ASPR
|
NIAID, NCI, CC
|
A network of researchers who collaborate to create new assays to measure the immune response to infection and gain further understanding of response variation and duration
|
|
The United States Renal Data System (USRDS)
|
Resource Development
|
CMS, HRSA
|
NIDDK
|
The United States Renal Data System (USRDS) is a national data system that collects, analyzes, and distributes information about chronic kidney disease and end-stage renal disease (ESRD) in the United States. The missions of USRDS are: (1) To characterize the total renal patient population and describe the distribution of patients by socio-demographic variables across treatment modalities; (2) To report on the incidence, prevalence, mortality rates, and trends over time of renal disease by primary diagnosis, treatment modality and other variables; (3) To develop and analyze data on the effect of various modalities of treatment by disease and patient group categories; (4) To identify problems and opportunities for more focused special studies of renal research issues; (5) To conduct cost effectiveness studies and other economic studies of ESRD; and (6) To make the data available to investigators, and by supporting investigator-initiated projects, to conduct biomedical and economic analyses of ESRD patients.
|
|
Tissue Chip Testing Centers (TCTC)
|
Research Initiative
|
FDA
|
NCATS
|
The National Center for Advancing Translational Science (NCATS) funded Tissue Chip Testing Centers (TCTC) where scientists have used a reference set of validation compounds vetted by pharmaceutical representatives through an NCATS partnership with the IQ Consortium and the Food and Drug Administration (FDA) to run tests to determine functionality, reproducibility, robustness, and reliability in these organ on chip model platforms. The TCTC scientists coordinated activities among Tissue Chip program-funded investigators and the FDA to support the validation of these chips, with the goal of getting chips to be used widely as a validated research tool and qualified for use in pre-clinical drug testing. The NextGen TCTCs funded in 2018 continued these goals, with a focus on building a self-sustaining financial business model for continuation of the TCTCs after the end of their funding periods. The Microphysiological Systems Database Center is also being supported by NCATS as a federated data warehouse that integrates tissue chips data with other pre-clinical and clinical datasets in order to establish utility and functionality of tissue chips in drug development.
|
|
Tobacco and Nicotine Research Interest Group (TANRIG)
|
Committee, Work group, Advisory group, or Task Force
|
CDC, SAMHSA, FDA, CMS
|
ODP, FIC, NCI, NEI, NHGRI, CSR, NCCIH, NIAMS, NIMH
|
The Tobacco and Nicotine Research Interest Group (TANRIG) was formed in January 2003 with the goal of increasing collaboration, coordination, and communication of tobacco- and nicotine-related research among National Institutes of Health Institutes and Centers, as well as with other relevant US Department of Health and Human Services agencies.
|
|
Tobacco Centers of Regulatory Science (TCORS)
|
Research Initiative
|
FDA
|
ODP
|
The Tobacco Regulatory Science Program located in the National Institutes of Health (NIH) Office of Disease Prevention coordinates the trans-NIH collaboration effort with the Food and Drug Administration (FDA) Center for Tobacco Products to conduct research that is needed to ensure that US tobacco regulatory actions and activities are based on sound and relevant scientific evidence. The U54 Tobacco Centers of Regulatory Science (TCORS) are the centerpiece of this NIH-FDA collaboration. The TCORS are expected to demonstrate research excellence and leadership in tobacco regulatory science that will contribute to the science base that FDA will use to develop meaningful product regulation, which will, in turn, reduce the toll of tobacco-related disease, disability, and death in the United States. Essential elements of the TCORS include at least three theoretically grounded, strong research projects with an integrative theme; an Administrative Core and other cores as needed; the ability to conduct developmental/pilot and time-sensitive research; and a program for career development. Nine TCORS, made up of scientists with a broad range of expertise (e.g., epidemiology, economics, toxicology, addictions, and marketing) are currently funded.
|
|
Tobacco Product Disease Risks
|
Research Initiative
|
FDA
|
NCI
|
NCI and the FDA-Center for Tobacco Products, in collaboration with the US Census Bureau, co-lead this study, which harmonizes data on cigarette, cigar, and pipe use from various Tobacco Use Supplements that have been administered over the years as part of the Current Population Survey. The participants in these surveys have been followed for mortality by linkage to the National Death Index. These data are used to provide contemporary estimates of the mortality risks of daily and non-daily use of cigarettes, pipes, and cigars. The first manuscript from the project is in press.
|
|
Tobacco Regulatory Science Program (TRSP)
|
Research Initiative
|
FDA
|
ODP, CSR, NCI, NHLBI, NIAAA, NICHD, NIDA, NIEHS, OD/OER
|
Located in the National Institutes of Health (NIH) Office of Disease Prevention, the Tobacco Regulatory Science Program (TRSP) coordinates the trans-NIH collaborative effort with the US Food and Drug Administration’s (FDA) Center for Tobacco Products (CTP) to conduct research to support its regulatory activities over tobacco products. Within the framework of the Tobacco Control Act, the NIH and FDA formed an interagency partnership to foster tobacco regulatory research. The NIH has the infrastructure for the solicitation, review, and management of research. The FDA has expertise in tobacco regulatory science and the authority and resources to support research responsive to FDA’s regulatory authority. Support from FDA was used to fund grants and to provide administrative support and oversight to manage Funding Opportunity Announcements (FOA), application review, policy implementation and oversight, and communicating and reporting to a variety of sources.
|
|
Tobacco Use Supplement to Current Population Survey (TUS-CPS)
|
Health Survey
|
CDC, FDA
|
NCI, NIMHD
|
The Tobacco Use Supplement to the Current Population Survey (TUS-CPS) is an National Cancer Institute (NCI)-sponsored survey of tobacco use that has been administered as part of the US Census Bureau's Current Population Survey approximately every 3-4 years since 1992-93.
|
|
Toxicology in the 21st Century (Tox 21)
|
Resource Development
|
FDA
|
NCATS, NIEHS
|
The Toxicology in the 21st Century (Tox21) program is a federal collaboration among National Institutes of Health(NIH) National Center for Advancing Translational Science (NCATS) and the National Toxicology Program at the National Institute of Environmental Health Sciences; the Environmental Protection Agency; and the Food and Drug Administration. Tox21 researchers aim to develop better toxicity assessment methods to quickly and efficiently test whether certain chemical compounds have the potential to disrupt processes in the human body that may lead to negative health effects.
|
|
Toxicology in the 21st Century Federal Consortium (NTP NCATS Interagency Agreement, ES-7020-01, Year 11) (Tox21)
|
Research Initiative
|
FDA
|
NIEHS, NCATS
|
Tox21 is a US federal research collaboration focused on driving the evolution of Toxicology in the 21st Century by developing methods to rapidly and efficiently evaluate the safety of commercial chemicals, pesticides, food additives/contaminants, and medical products.
This IAA is designed to explore new, effective, primarily non-animal methods and technologies to elucidate critically important questions pertaining to impacts of environmental exposures on cellular toxicity pathways that may lead to human disease. A major focus is the development of innovative approaches in toxicology assessment.
|